labetalol has been researched along with ethanolamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Asai, S; Fukushima, M; Horinouchi, T; Koike, K | 1 |
2 other study(ies) available for labetalol and ethanolamine
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Partial agonistic activity of labetalol, the arylethanolamine, on beta 3-adrenoceptors in the guinea-pig gastric fundus.
Topics: Adrenergic beta-3 Receptor Agonists; Animals; Dose-Response Relationship, Drug; Ethanolamine; Gastric Fundus; Guinea Pigs; In Vitro Techniques; Labetalol; Male; Muscle Relaxation; Receptors, Adrenergic, beta-3 | 2002 |